Porter Roger J, Nohria Virinder, Rundfeldt Chris
Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia 30322, USA.
Neurotherapeutics. 2007 Jan;4(1):149-54. doi: 10.1016/j.nurt.2006.11.012.
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.
瑞替加滨是一种新型抗癫痫药物，通过钾通道发挥作用，在多种癫痫动物模型中均有活性。它在几种临床前疼痛模型中也有效。该药物已在I期和II期研究中进行了广泛研究，结果非常有前景。大多数患者的最大耐受剂量为1200毫克/天。不良反应主要与中枢神经系统相关且较为轻微；大多数发生在各项研究的滴定期。目前，瑞替加滨正处于两项关键的III期研究中。
